Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22863819 | 0.80 | PDE2A (0.42) | PDE2ACYP3A4ALDH1A1LMNA | |
| SCHEMBL18647493 | 0.76 | PDE2A (0.43) | PDE2ARORCLMNA | |
| SCHEMBL24772476 | 0.73 | PDE2A (0.58) | PDE2AALDH1A1 | |
| SCHEMBL19805986 | 0.73 | PDE2A (0.41) | PDE2APNMTRORCALDH1A1LMNA | |
| SCHEMBL23489786 | 0.73 | CYP2D6 (0.33) | PDE2ACYP2D6 | |
| SCHEMBL24696003 | 0.72 | PDE2A (0.34) | PDE2A | |
| SCHEMBL18559007 | 0.71 | PDE2A (0.36) | PDE2ARORC | |
| SCHEMBL21146831 | 0.71 | PDE2A (0.40) | PDE2ARORC | |
| SCHEMBL19374773 | 0.71 | NR3C1 (0.30) | — | |
| SCHEMBL19121188 | 0.68 | PDE2A (0.37) | PDE2ACYP1A2CYP3A4CYP2D6RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947260-B2 | Phosphinolactone derivatives and pharmaceutical uses thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2021-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947260-B2 | Phosphinolactone derivatives and pharmaceutical uses thereof | PHOSPHO1, PSEN1, PSEN2 | PDE2A 1688/4885CYP1A2 1220/4885CYP3A4 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.